Outline:
Strong Financial Performance and Strategic Expansion Highlight GenScript’s 2025 Progress
GenScript Biotech Corporation, a leading player in the life sciences sector, has reported impressive interim results for the first half of 2025. The company’s performance reflects its ability to achieve profitable growth through strategic globalization, advanced technology, and continuous innovation. These results are a testament to the company’s strong business model and its commitment to delivering value to both customers and shareholders.
Robust Financial Growth
The company recorded consolidated revenue of approximately US$518.8 million for H1 2025, marking an exceptional increase of 81.9% year-over-year. This significant growth was driven by strong demand across all business segments and expansion into key international markets. Gross profit also saw a remarkable rise of 140.1%, reaching US$320.6 million. Adjusted net profit from continuing operations surged by 509.6% to US$178 million, showcasing the company’s operational efficiency and margin resilience.
Key Highlights of the First Half
- Revenue: US$518.8 million, reflecting broad-based growth across all business segments and geographies.
- Gross Profit: US$320.6 million, driven by improved capacity utilization and a premium product mix.
- Adjusted Net Profit: US$178.0 million, highlighting scalable profitability and enhanced operational leverage.
- Global Presence: Meaningful growth observed in all regions, with increased contributions from international markets.
- Sustainability Leadership: Industry-leading ESG ratings that reinforce long-term stakeholder value.
Strategic Growth Drivers
GenScript’s success is fueled by several key drivers, including innovation and excellence in its gene-to-protein platform. The Life Science Services and Products segment generated US$247.6 million in revenue, representing a 11.3% year-over-year increase. This growth was supported by breakthroughs in gene synthesis throughput and a 52% uplift in the protein business, driven by rising demand, especially from AI-driven drug discovery companies.
The company’s CDMO business under ProBio experienced a remarkable rebound, reporting US$246.9 million in revenue—an extraordinary 511.1% increase year-over-year. Adjusted gross margins expanded significantly to 73.6%, reflecting improved capacity utilization and operational efficiencies. ProBio has out-licensed 16 assets, with four currently in clinical development. Upcoming milestones, such as potential CD3 VHH out-licensing by late 2025 or early 2026, offer strong visibility into future revenue streams.
Innovation in Industrial Synthetic Biology
Bestzyme, GenScript’s industrial synthetic biology products unit, saw a revenue growth of 8.4%, driven by market share gains and continued trust from key accounts. With 61 patents granted and 61 new applications filed, Bestzyme is at the forefront of industry innovation. Its innovative synthetic biologic product, sweet protein, has received FDA GRAS status, and commercial manufacturing is expected to begin in mid-2026.
Strengthening Global Reach
GenScript’s global production and R&D footprint, with major facilities in the U.S., Europe, and Asia, supports over 60% automation penetration. This enables resilient supply chains and rapid responsiveness to customer needs. The company’s August 8 global brand relaunch, combined with its industry-leading Net Promoter Score, strengthens customer loyalty and commercial momentum, driving win rates, pricing power, and adoption of integrated, higher-margin solutions.
Commitment to ESG
GenScript remains committed to sustainability, with its ESG framework aligned to global best practices. The company has earned top-tier recognition, including an MSCI AA rating, EcoVadis Silver Medal, Sustainalytics “Low Risk” designation, and an improved S&P Global Corporate Sustainability Assessment score of 60. It is also included in the FTSE4Good Index Series. These achievements highlight GenScript’s dedication to responsible growth and its appeal to investors who prioritize ESG as a key driver of long-term value.
Future Outlook
Looking ahead, GenScript anticipates continued growth backed by scaling automation, global brand strength, and an expanding pipeline of innovative solutions. The company is well-positioned to sustain its leadership in biotechnology, delivering differentiated solutions and creating elevated shareholder value in an evolving global healthcare and biotech landscape.